Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th
MIAMI, July 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
Pregnancy
Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Progyny is First Fertility Benefits Solution to Publish Outcomes with Independent Validation
Progyny Outcomes Consistently Exceed National Benchmarks Across Key Clinical Measures of Fertility Success Progyny's Superior Clinical Outcomes The outcomes of...
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼¹ IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome
-- European Commission decision anticipated in fourth quarter of 2022 -- BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals,...
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand...
FDA Approves QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17
CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA)...
SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update
Data show that 71% of 24 patients with recurrent vulvovaginal candidiasis (RVVC) who failed to respond to a three-day regimen...
MINDBAR, THE MOBILE GYM FOR YOUR MIND, IS CHANGING THE GAME OF HOW WE APPROACH MENTAL HEALTHCARE
The New Wellness Platform is Redefining Accessible Mental Healthcare, Putting the Benefits of Therapy in Members' Hands With the Launch...
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the...
Genetic Testing During Pregnancy – Good or Bad?
Genetic testing is increasing in popularity for many different areas of healthcare, and it’s well-funded and expected to keep advancing...